Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development
Authors
Keywords
-
Journal
Acta Pharmaceutica Sinica B
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2020-12-16
DOI
10.1016/j.apsb.2020.12.011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
- (2020) Christoph Fraune et al. ANNALS OF SURGICAL ONCOLOGY
- PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA).
- (2020) E. Gabriela Chiorean et al. JOURNAL OF CLINICAL ONCOLOGY
- A pilot study of intratumoral SD-101 (toll-like receptor 9 agonist), nivolumab, and radiotherapy for treatment of chemotherapy-refractory metastatic pancreatic adenocarcinoma.
- (2020) Justin Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
- (2019) Hyun Lee et al. MOLECULES
- A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).
- (2019) Andrea Wang-Gillam et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy in pancreatic cancer: New hope or mission impossible?
- (2019) Jiahong Jiang et al. CANCER LETTERS
- MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
- (2019) Philippe Alexandre Cassier et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
- (2019) Davide Melisi et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
- (2019) Chin-King Looi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer
- (2019) Janet E. Murphy et al. JAMA Oncology
- Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
- (2019) André F. Oliveira et al. Frontiers in Oncology
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers
- (2019) Yuji Eso et al. JOURNAL OF GASTROENTEROLOGY
- 613PPhase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
- (2019) N Halama et al. ANNALS OF ONCOLOGY
- IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer
- (2019) Guoping Ding et al. BMC CANCER
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
- (2019) Devalingam Mahalingam et al. CLINICAL CANCER RESEARCH
- Comprehensive molecular profiling of the B7 family in gastrointestinal cancer
- (2018) Qijie Zhao et al. CELL PROLIFERATION
- Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
- (2018) Yinghao Zhao et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
- (2018) Zishuo I. Hu et al. CLINICAL CANCER RESEARCH
- Regulatory T cells increase after treatment with poly (ADP-ribose) polymerase-1 inhibitor in ischemic stroke patients
- (2018) Min-Young Noh et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
- (2018) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy beyond immune checkpoint inhibitors
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
- (2018) Mohamed E. Salem et al. MOLECULAR CANCER RESEARCH
- Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
- (2018) Maureen L. Drakes et al. Journal of Ovarian Research
- Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.
- (2018) Niels Halama et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
- (2018) Danyang Sun et al. Therapeutics and Clinical Risk Management
- Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
- (2018) Mei Gao et al. BRITISH JOURNAL OF CANCER
- Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment
- (2018) Daisuke Umezu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
- (2018) Shravanti Macherla et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
- (2018) Monika C. Brunner-Weinzierl et al. Frontiers in Immunology
- PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
- (2017) Tomas Jelinek et al. IMMUNOLOGY
- Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
- (2017) Varun Sasidharan Nair et al. IMMUNOLOGY AND CELL BIOLOGY
- Immunotherapy for Prostate Cancer: Where We Are Headed
- (2017) Giuseppe Schepisi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Alok A. Khorana et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
- (2017) Paolo A. Ascierto et al. Journal of Translational Medicine
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines
- (2017) Toshifumi Doi et al. ONCOLOGY REPORTS
- Expansion of cancer germline antigen–specific cytotoxic T lymphocytes for immunotherapy
- (2017) Deepa Kolaseri Krishnadas et al. TUMOR BIOLOGY
- Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
- (2017) Jonas R.M. Van Audenaerde et al. Oncotarget
- Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
- (2017) Seung Tae Kim et al. Oncotarget
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer
- (2017) Daisuke Imai et al. Cancer Medicine
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
- (2017) Chunwan Lu et al. OncoImmunology
- Expression of programmed death ligand 1 (PD-L1) in malignant and nonmalignant pancreatic tissue.
- (2017) Saqib Razzaque et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer
- (2017) Tao Shen et al. Scientific Reports
- Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model
- (2016) Lydia Dyck et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
- (2016) Donnele Daley et al. CELL
- T-cell exhaustion in tuberculosis: pitfalls and prospects
- (2016) Nargis Khan et al. CRITICAL REVIEWS IN MICROBIOLOGY
- Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti–PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors
- (2016) J.C. Sachdev et al. GYNECOLOGIC ONCOLOGY
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer.
- (2016) Austin G. Duffy et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib + durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study.
- (2016) Erkut Hasan Borazanci et al. JOURNAL OF CLINICAL ONCOLOGY
- nab-paclitaxel (nab-P) + nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
- (2016) Irfan Firdaus et al. JOURNAL OF CLINICAL ONCOLOGY
- Prolonged PD1 Expression on Neonatal Vδ2 Lymphocytes Dampens Proinflammatory Responses: Role of Epigenetic Regulation
- (2016) Haoting Hsu et al. JOURNAL OF IMMUNOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Immune checkpoint therapy for pancreatic cancer
- (2016) Henrik Johansson et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer
- (2016) Yu Wang et al. Oncotarget
- Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
- (2016) Nadia M. Luheshi et al. Oncotarget
- Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma
- (2016) Angela Diana et al. Oncotarget
- Pancreatic cancer
- (2016) Jorg Kleeff et al. Nature Reviews Disease Primers
- Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact
- (2015) Takuya Komura et al. CANCER SCIENCE
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
- (2015) Mihaela Angelova et al. GENOME BIOLOGY
- Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
- (2015) R. Stewart et al. Cancer Immunology Research
- Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
- (2015) Isabelle Le Mercier et al. Frontiers in Immunology
- Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
- (2015) Laura Rosa Brunet et al. OncoImmunology
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
- (2014) Kayoko Waki et al. CANCER SCIENCE
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Programmed death-1 pathway in cancer and autoimmunity
- (2014) Ariel Pedoeem et al. CLINICAL IMMUNOLOGY
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
- (2014) Emanuela Romano et al. Journal of Translational Medicine
- In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
- (2014) C. Wang et al. Cancer Immunology Research
- Vaccine therapy for pancreatic cancer
- (2014) Bulent Salman et al. OncoImmunology
- Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
- (2013) Y Ino et al. BRITISH JOURNAL OF CANCER
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Deciphering the role of stroma in pancreatic cancer
- (2013) Meghna Waghray et al. CURRENT OPINION IN GASTROENTEROLOGY
- Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations
- (2013) Haoyu Sun et al. CYTOKINE
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer
- (2013) XIAO SONG et al. ONCOLOGY REPORTS
- Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study
- (2013) Daniela Basso et al. PLoS One
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the B7 Family of Co-Stimulatory Molecules
- (2012) Joseph R. Podojil et al. BIODRUGS
- Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal
- (2012) Y. Lu et al. BLOOD
- Vaccines for Pancreatic Cancer
- (2012) Kevin C. Soares et al. CANCER JOURNAL
- Cellular Constituents of Immune Escape within the Tumor Microenvironment
- (2012) S. P. Kerkar et al. CANCER RESEARCH
- Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
- (2012) J. B. Mitchem et al. CANCER RESEARCH
- Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
- (2012) Esdy N. Rozali et al. Clinical & Developmental Immunology
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- The Pancreas Cancer Microenvironment
- (2012) C. Feig et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Antibodies Against B7-DC with Differential Binding Properties Exert Opposite Effects
- (2012) Patcharee Ritprajak et al. HYBRIDOMA
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- The Desmoplastic Stroma Plays an Essential Role in the Accumulation and Modulation of Infiltrated Immune Cells in Pancreatic Adenocarcinoma
- (2011) Vegard Tjomsland et al. Clinical & Developmental Immunology
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
- (2011) R. R. Huang et al. CLINICAL CANCER RESEARCH
- PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease
- (2011) Holger Krönig et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2
- (2010) S. Huber et al. BLOOD
- The CD4-like molecule LAG-3, biology and therapeutic applications
- (2010) Sophie Sierro et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
- (2010) Mark E. Davis et al. NATURE
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
- (2010) N. Jain et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma
- (2010) Liancai Wang et al. WORLD JOURNAL OF SURGERY
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
- (2009) C. J. Workman et al. JOURNAL OF IMMUNOLOGY
- PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
- (2009) O Akbari et al. Mucosal Immunology
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
- (2009) D. Schonfeld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer
- (2008) Martin Loos et al. CANCER LETTERS
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
- B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression
- (2008) Lei Geng et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
- (2008) Y. Onishi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
- (2008) L. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 trafficking and surface expression
- (2008) Elke Valk et al. TRENDS IN IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now